Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Witzig

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Blood Cancer Journal|August 29, 2015
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaA J Novak, Y W Asmann, M J Maurer, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trialT E Witzig, K Tobinai, L Rigacci, et al.
Blood Cancer Journal|November 10, 2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsA Castellino, A Chiappella, B R LaPlant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Blood Cancer Journal|August 29, 2015
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaA J Novak, Y W Asmann, M J Maurer, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trialT E Witzig, K Tobinai, L Rigacci, et al.
Blood Cancer Journal|November 10, 2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsA Castellino, A Chiappella, B R LaPlant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)A Younes, P Hilden, B Coiffier, et al.
Pageof 17